ASX announcements


 
18-Apr-2024    Proposed issue of securities - BXN  
 
18-Apr-2024    Bioxyne Receives Firm Commitments to Raise $1.45 Million  
 
29-Feb-2024    Half Yearly Report and Accounts  
 
5-Feb-2024    BXN Awarded GMP Manufacturing License for Medical Cannabis  
 
5-Feb-2024    Quarterly Report Listing Rule 4.7C.3  
 
29-Jan-2024    Quarterly Activities/Appendix 4C Cash Flow Report  
 
17-Nov-2023    Final Director's Interest Notice  
 
17-Nov-2023    Retirement of Director  
 
17-Nov-2023    Results of Meeting  
 
17-Nov-2023    Annual General Meeting Presentation  
 
31-Oct-2023    Quarterly Activities/Appendix 4C Cash Flow Report  
 
19-Oct-2023    BLS Builds Medicinal Business In Australia  
 
18-Oct-2023    Letter to Shareholders re Annual General Meeting Notice  
 
18-Oct-2023    Notice of Annual General Meeting/Proxy Form  
 
17-Oct-2023    Change of Director's Interest Notice  
 
5-Oct-2023    AGM Date 2023 and Closing Date for Director Nominations  
 
29-Sep-2023    Annual Report to shareholders  
 
29-Sep-2023    Appendix 4G and Corporate Governance Statement  
 
31-Aug-2023    Preliminary Final Report  
 
31-Jul-2023    Quarterly Activities/Appendix 4C Cash Flow Report  
 
17-Jul-2023    BLS Extends Amazon Footprint into US and Japan  
 
22-May-2023    Bioxyne Completes Acquisition of Breathe Life Sciences  
 
5-May-2023    Results of Meeting  
 
24-Apr-2023    Quarterly Activities/Appendix 4C Cash Flow Report  
 
20-Mar-2023    Bioxyne Executes SPA to Acquire Breathe Life Sciences  
 
27-Feb-2023    Becoming a substantial holder  
 
23-Feb-2023    Half Yearly Report and Accounts  
 
27-Jan-2023    Quarterly Activities/Appendix 4C Cash Flow Report  
 
19-Dec-2022    BXN to Acquire Health & Wellness Co Breathe Life Sciences  
 
30-Nov-2022    New Constitution  
 
28-Nov-2022    Results of Meeting  
 
16-Nov-2022    Cleansing Notice  
 
16-Nov-2022    Application for quotation of securities - BXN  
 
15-Nov-2022    Proposed issue of securities - BXN  
 
3-Nov-2022    Notification of cessation of securities - BXN  
 
31-Oct-2022    Quarterly Activities/Appendix 4C Cash Flow Report  
 
28-Oct-2022    Letter to Shareholders on Annual General Meeting Notice  
 
28-Oct-2022    Notice of Annual General Meeting/Proxy Form  
 
26-Oct-2022    Cleansing Notice  
 
24-Oct-2022    Joins Asian Partner & Sells 49% of Direct Selling Business  
 
30-Sep-2022    Appendix 4G and Corporate Governance Statement  
 
30-Sep-2022    Annual Report to shareholders  
 
30-Aug-2022    Preliminary Final Report  
 
28-Jul-2022    Quarterly Activities/Appendix 4C Cash Flow Report  
 
30-Jun-2022    Initial Director's Interest Notice  
 
30-Jun-2022    Final Director's Interest Notice  
 
8-Jun-2022    Board and Management Changes  
 
28-Apr-2022    Quarterly Activities/Appendix 4C Cash Flow Report  
 
22-Feb-2022    Appendix 4D and Interim Report  
 
31-Jan-2022    Quarterly Activities/Appendix 4C Cash Flow Report  
 
30-Nov-2021    Results of Meeting  
 
4-Nov-2021    Reinstatement to Official Quotation  
 
4-Nov-2021    Bioxyne Not to Proceed with Proposed Acquisition  
 
29-Oct-2021    Letter to Shareholders on Annual General Meeting  
 
29-Oct-2021    Notice of Annual General Meeting/Proxy Form  
 
29-Oct-2021    Suspension from Quotation  
 
28-Oct-2021    Quarterly Activities/Appendix 4C Cash Flow Report  
 
27-Oct-2021    Trading Halt  
 
27-Oct-2021    Pause in Trading  
 
30-Sep-2021    Appendix 4G and Corporate Governance Statement  
 
30-Sep-2021    Annual Report to shareholders  
 
30-Sep-2021    Explanatory Note to the 2021 Annual Report  
 
31-Aug-2021    Preliminary Final Report  
 
22-Jul-2021    Quarterly Activities/Appendix 4C Cash Flow Report  
 
30-Apr-2021    Appendix 4C - quarterly  
 
21-Apr-2021    Response to ASX Price Query  
 
25-Feb-2021    Appendix 4D and Half Year Accounts  
 
29-Jan-2021    Appendix 4C - Quarterly December 2020  
 
26-Nov-2020    Results of Meeting  
 
29-Oct-2020    Appendix 4C - quarterly  
 
27-Oct-2020    Notice of Annual General Meeting/Proxy Form  
 
30-Sep-2020    Appendix 4G and Corporate Governance  
 
30-Sep-2020    Annual Report to shareholders  
 
31-Aug-2020    Preliminary Final Report  
 
21-Aug-2020    Response to ASX Price Query  
 
31-Jul-2020    Appendix 4C - quarterly  
 
1-May-2020    Appendix 4C Revised  
 
30-Apr-2020    Appendix 4C - quarterly  
 
14-Apr-2020    Market Update  
 
28-Feb-2020    Appendix 4D and Half Year Accounts  
 
31-Jan-2020    Appendix 4C - quarterly  
 
20-Jan-2020    Change of Share Registry  
 
27-Nov-2019    Change of Directors Interest Notice X 4  
 
27-Nov-2019    Appendix 3B  
 
25-Nov-2019    Results of Meeting  
 
31-Oct-2019    Appendix 4C - quarterly  
 
25-Oct-2019    Notice of Annual General Meeting/Proxy Form  
 
9-Oct-2019    Change of Director's Interest Notice  
 
30-Sep-2019    Annual Report to shareholders  
 
30-Sep-2019    Explanatory Note to the 2019 Annual Report  
 
30-Sep-2019    Appendix 4G and Corporate Governance Statement  
 
28-Aug-2019    Preliminary Final Report  
 
31-Jul-2019    Appendix 4C - quarterly  
 
4-Jun-2019    Change of Director's Interest Notice  
 
29-Apr-2019    Appendix 4C - quarterly  
 
1-Apr-2019    Market Update  
 
20-Feb-2019    Appendix 4D and Half Year Accounts  
 
30-Jan-2019    Appendix 4C - quarterly  
 
21-Jan-2019    Final Director's Interest Notice  
 
17-Jan-2019    Director Resignation  
 
21-Dec-2018    Change of Directors Interest Notice X 5  
 
21-Dec-2018    Appendix 3B  
 
29-Nov-2018    Results of Meeting  
 
29-Oct-2018    Quarterly Activities Report  
 
29-Oct-2018    Appendix 4C - quarterly  
 
25-Oct-2018    Notice of Annual General Meeting/Proxy Form  
 
16-Oct-2018    Change of Director's Interest Notice  
 
28-Sep-2018    Annual Report to shareholders  
 
28-Sep-2018    Appendix 4G and Corporate Governance Statement  
 
25-Sep-2018    Bioxyne Expands to Indonesia with Acquisition  
 
31-Aug-2018    Preliminary Final Report  
 
6-Aug-2018    Change of Director's Interest Notice  
 
27-Jul-2018    Quarterly Activities and Quarterly Cash Flow Report  
 
16-Jul-2018    Change of Director's Interest Notice  
 
10-Jul-2018    Change of Director's Interest Notice  
 
22-Jun-2018    Change of Director's Interest Notice  
 
20-Jun-2018    Change of Director's Interest Notice  
 
12-Jun-2018    Bioxyne to Distribute GRAYNS Starch Reducing Rice Cooker  
 
21-May-2018    Clarification to Announcement  
 
21-May-2018    Expands to Thailand, Philippines, Myanmar, Cambodia,  
 
4-May-2018    Initial Director's Interest Notice  
 
1-May-2018    Appointment of Non-Executive Director  
 
30-Apr-2018    Securities Trading Policy - Updated  
 
27-Apr-2018    Quarterly Activities and Quarterly Cash Flow Reports  
 
19-Mar-2018    Investor Update  
 
1-Mar-2018    Response to ASX Query Letter  
 
28-Feb-2018    Appendix 4D and Interim Financial Report  
 
26-Feb-2018    Unique NZ Colostrum Honey Dairy Product for China and S.E.A  
 
16-Feb-2018    Final Director's Interest Notice  
 
15-Feb-2018    Director Resignation  
 
15-Feb-2018    Appendix 3B Corrected  
 
30-Jan-2018    Quarterly Activities and Quarterly Cash Flow Report Dec 17  
 
17-Jan-2018    Change of Director's Interest Notice  
 
16-Jan-2018    Additional New Products Launched for Direct Sales  
 
19-Dec-2017    Appendix 3B  
 
14-Dec-2017    Third Party Claim  
 
11-Dec-2017    Appendix 3B  
 
11-Dec-2017    Change of Directors Interest X 3  
 
11-Dec-2017    Positive Bioxyne Gut Health Clinical Trial Results  
 
7-Dec-2017    Change of Directors Interest Notice X 2  
 
7-Dec-2017    Bioxyne Launches NZ Dairy Formula Product in South East Asia  
 
7-Dec-2017    Appendix 3B Amended  
 
5-Dec-2017    Appendix 3B  
 
1-Dec-2017    Change of Share Registry  
 
28-Nov-2017    Results of Meeting  
 
15-Nov-2017    Letter to Optionholders  
 
1-Nov-2017    Change of Director's Interest Notice  
 
27-Oct-2017    Appendix 3B  
 
26-Oct-2017    Notice of Annual General Meeting/Proxy Form  
 
25-Oct-2017    Quarterly Activities Report and Appendix 4C  
 
25-Oct-2017    Malaysian Direct Selling Licence to Propel Bioxyne into MLM  
 
17-Oct-2017    Appendix 3B  
 
16-Oct-2017    Response to ASX Price Query Letter  
 
12-Oct-2017    Appendix 3B  
 
25-Sep-2017    Appendix 4G  
 
25-Sep-2017    Annual Report to shareholders  
 
22-Sep-2017    Appendix 3B  
 
18-Sep-2017    BXN Extends Product Range, New Website, Marketing Campaign  
 
31-Aug-2017    Appendix 4E Preliminary Final Report  
 
8-Aug-2017    Change in substantial holding  
 
4-Aug-2017    Directors Change in Interest X 3  
 
4-Aug-2017    Appendix 3B  
 
3-Aug-2017    Results of Meeting  
 
31-Jul-2017    Quarterly Activities Appendix 4C  
 
11-Jul-2017    Appendix 3B  
 
3-Jul-2017    Notice of General Meeting/Proxy Form  
 
26-Jun-2017    Change in substantial holding  
 
13-Jun-2017    Directors Initial Interest Notice X 2  
 
13-Jun-2017    Becoming a substantial holder  
 
13-Jun-2017    Appointment of Directors  
 
1-Jun-2017    Share Sale Facility for Unmarketable Parcels  
 
31-May-2017    Directors Change in Interest X 2  
 
30-May-2017    Appendix 3B  
 
26-May-2017    Rights Issue - Notification of Shortfall  
 
8-May-2017    Appendix 3B  
 
4-May-2017    Rights Issue - Letter to Ineligible Shareholders  
 
3-May-2017    Letter to Shareholders - Rights Issue  
 
3-May-2017    Prospectus - Rights Issue  
 
27-Apr-2017    Quarterly Activities and Cash Flow Report March 2017  
 
21-Apr-2017    Cleansing Statement  
 
21-Apr-2017    Appendix 3B  
 
19-Apr-2017    Letter to Optionholders  
 
19-Apr-2017    Listing Rule 7.1A Information  
 
19-Apr-2017    Appendix 3B  
 
19-Apr-2017    Acquires NZ Product Company for Direct Sales Asia Pacific  
 
13-Apr-2017    Trading Halt  
 
27-Feb-2017    Appendix 4D and Half Year Report  
 
21-Feb-2017    Bioxyne to Access Chinese Market for Online Sales via JD.com  
 
8-Feb-2017    Response to ASX Appendix 3Y Letter  
 
3-Feb-2017    Issue of Options, Appendix 3B, Appendix 3Y X 2  
 
25-Jan-2017    Quarterly Activities and Cash Flow Report Dec 2016  
 
13-Jan-2017    Change of Director's Interest Notice  
 
29-Dec-2016    Details of Company Address  
 
24-Nov-2016    Results of Meeting  
 
23-Nov-2016    AGM Notice - Amendment to Resolutions  
 
21-Nov-2016    AGM - Amendment to Resolutions  
 
18-Nov-2016    Final Director's Interest Notice  
 
18-Nov-2016    Director Resignation  
 
2-Nov-2016    Launch of Two Products Containing PCC Onto Australian Market  
 
26-Oct-2016    Quarterly Activities Report and Appendix 4C  
 
24-Oct-2016    Notice of Annual General Meeting/Proxy Form  
 
17-Oct-2016    Recruitment for Clinical Trial of Proprietary Probiotic PCC  
 
29-Sep-2016    Annual Report to shareholders  
 
29-Sep-2016    Appendix 4G and Corporate Governance Statement  
 
12-Sep-2016    Becoming a substantial holder  
 
9-Sep-2016    Ceasing to be a substantial holder  
 
1-Sep-2016    Management Restructure  
 
1-Sep-2016    Company Secretary Appointment/Details of Company Address  
 
30-Aug-2016    Appendix 4E - Preliminary Final Report  
 
28-Jul-2016    Appendix 4C - June Quarterly  
 
23-Jun-2016    Bioxyne Commences New Clinical Trial  
 
15-Jun-2016    Directors Equity Based Incentives  
 
5-May-2016    Board Exercises Options  
 
5-May-2016    Appendix 3B - Exercise of Directors' Options  
 
5-May-2016    Change of Director's Interest Notice - Patrick Ford  
 
5-May-2016    Change of Director's Interest Notice - Anthony Ho  
 
5-May-2016    Change of Director's Interest Notice - George Cameron-Dow  
 
26-Apr-2016    Appendix 4C - March quarterly  
 
31-Mar-2016    Bioxyne Announces 2016 Goals  
 
29-Mar-2016    Bioxyne Investor Presentation  
 
16-Mar-2016    Change of Director's Interest Notice - A Ho  
 
26-Feb-2016    Appendix 4D - Half Yearly Report and Accounts  
 
15-Feb-2016    Initial Director's Interest Notice - Dr Peter French  
 
15-Feb-2016    Appointment of Executive Director Dr Peter French  
 
4-Feb-2016    Tony Ho - Change of Director's Interest Notice  
 
21-Jan-2016    Appendix 4C - December Quarterly  
 
20-Nov-2015    Results of Annual General Meeting  
 
11-Nov-2015    Mariposa Health Inc. Investment Update  
 
2-Nov-2015    Change of Director's Interest Notice - Patrick Ford  
 
29-Oct-2015    Appendix 4C - September Quarterly  
 
20-Oct-2015    2015 Notice of Annual General Meeting and Proxy Form  
 
1-Oct-2015    Appendix 4G  
 
30-Sep-2015    2015 Annual Report to Shareholders  
 
31-Aug-2015    Appendix 4E - Preliminary Final Report  
 
17-Aug-2015    2015 Financial Year Profit Update  
 
30-Jul-2015    Appendix 4C - June Quarterly  
 
20-May-2015    Becoming a Substantial Holder - Ondek Pty Ltd  
 
20-May-2015    Change of Director's Interest Notice - George Cameron-Dow  
 
20-May-2015    Ceasing to be a substantial holder - Fleming  
 
28-Apr-2015    Appendix 4C - March Quarterly  
 
16-Apr-2015    Change of Director's Interest Notice - George Cameron-Dow  
 
27-Feb-2015    Appendix 4D - Half Yearly Report and Accounts  
 
10-Feb-2015    Change of Director's Interest Notice - P Ford  
 
30-Jan-2015    Change of Director's Interest Notice - A Ho  
 
28-Jan-2015    Appendix 4C - December Quarterly  
 
11-Dec-2014    Change of Director's Interest Notice - A Ho  
 
11-Dec-2014    Change of Director's Interest Notice - P Ford  
 
11-Dec-2014    Change of Director's Interest Notice - G Cameron-Dow  
 
11-Dec-2014    Appendix 3B - Issue of Employee Options  
 
28-Nov-2014    Change of Registered Office  
 
28-Nov-2014    Results of 2014 Annual General Meeting  
 
24-Nov-2014    Change of Director's Interest Notice - P Ford  
 
21-Nov-2014    Change of Director's Interest Notice - A Ho  
 
29-Oct-2014    Notice of 2014 Annual General Meeting/Proxy Form  
 
27-Oct-2014    Appendix 4C - September Quarterly  
 
30-Sep-2014    Annual Report to Shareholders  
 
18-Sep-2014    Appointment of Strategic Marketing Consultant  
 
29-Aug-2014    Appendix 4E - Preliminary Final Report  
 
19-Aug-2014    Top 20 securityholders  
 
28-Jul-2014    Appendix 4C - June Quarterly  
 
21-Jul-2014    Initial Director's Interest Notice - George Cameron-Dow  
 
21-Jul-2014    Final Director's Interest Notice - Jeremy Curnock-Cook  
 
21-Jul-2014    Resignation and Appointment of Directors  
 
21-Jul-2014    Change of Director's Interest Notice - Jeremy Curnock-Cook  
 
21-Jul-2014    Ceasing to be substantial holder - Phillip Asset Management  
 
21-Jul-2014    Becoming a substantial holder - Fleming SG Capital SO  
 
16-May-2014    Options Expiry  
 
30-Apr-2014    Appendix 4C - March Quarterly  
 
4-Apr-2014    Appendix 3B - Quotation Following ASX Escrow Release  
 
1-Apr-2014    Change of Director's Interest Notice - P Ford  
 
18-Mar-2014    Release of Shares from Escrow  
 
28-Feb-2014    Half Yearly Report and Accounts  
 
25-Feb-2014    Change of Director's Interest Notice - P Ford  
 
25-Feb-2014    Completion of the Sale of HI-164 Program  
 
19-Feb-2014    Change of Director's Interest Notice - P Ford  
 
14-Feb-2014    Change in substantial holding  
 
31-Jan-2014    Appendix 4C - December Quarterly  
 
31-Jan-2014    Amended Change of Director's Interest Notices  
 
30-Jan-2014    Change of Director's Interest Notice - P Ford  
 
30-Jan-2014    Change of Director's Interest Notice - J C Cook  
 
30-Jan-2014    Change of Director's Interest Notice - A P Ho  
 
27-Dec-2013    Appendix 3B - EGM Approved Share and Option Issues  
 
23-Dec-2013    Results of EGM  
 
4-Dec-2013    Expiry of Unquoted Options  
 
2-Dec-2013    Bioxyne Limited CEO Steps Down  
 
2-Dec-2013    Sale of HI-164OV Hunter Immunology Pty Ltd  
 
29-Nov-2013    Results of 2013 AGM  
 
22-Nov-2013    Notice of Extraordinary General Meeting/Proxy Form  
 
6-Nov-2013    Response to ASX query  
 
31-Oct-2013    Appendix 4C - September Quarterly  
 
31-Oct-2013    Notice of Annual General Meeting/Proxy Form  
 
23-Sep-2013    30 June 2013 Full Year Statutory Accounts  
 
30-Aug-2013    Appendix 4E - Preliminary Final Report  
 
6-Aug-2013    Response to ASX query  
 
31-Jul-2013    Appendix 4C - June Quarterly  
 
6-Jun-2013    Company Secretary Resignation  
 
23-May-2013    Termination of proposed acquisition - Vitality Devices  
 
30-Apr-2013    Appendix 4C - quarterly - 31 March 2013  
 
4-Apr-2013    Appendix 3B - Quotation of Escrowed Stock  
 
15-Mar-2013    Release of Shares from Escrow  
 
7-Mar-2013    Appendix 3B and s708A(6) Notice - Completion of Placement  
 
4-Mar-2013    Vitality Devices Acquisition Update  
 
28-Feb-2013    Half Yearly Report and Accounts to 31 December 2012  
 
20-Feb-2013    Completion of placement follow up  
 
20-Feb-2013    Reinstatement to Official Quotation  
 
20-Feb-2013    Completion of Placement  
 
20-Feb-2013    Suspension Request  
 
20-Feb-2013    Suspension from Official Quotation  
 
18-Feb-2013    Appointment of new CFO and change of registered office  
 
18-Feb-2013    Trading Halt  
 
18-Feb-2013    Proposed Acquisition of Vitality  
 
18-Feb-2013    Status Review HI 164OV Further Update  
 
12-Feb-2013    Appoints New Company Secretary  
 
5-Feb-2013    Response to ASX query  
 
31-Jan-2013    Appendix 4C - quarterly  
 
25-Jan-2013    Change of Director's Interest Notice  
 
21-Jan-2013    Update and Status review of HI-164 therapy for COPD  
 
11-Jan-2013    Change of Director's Interest Notice  
 
17-Dec-2012    Final Director's Interest Notice  
 
17-Dec-2012    Initial Director's Interest Notice  
 
13-Dec-2012    APPOINTMENT OF CHIEF EXECUTIVE OFFICER AND NEW DIRECTOR  
 
3-Dec-2012    Change in Board Composition  
 
3-Dec-2012    Final Director's Interest Notice  
 
3-Dec-2012    Final Director's Interest Notice - IM  
 
29-Nov-2012    BIOXYNE Results of Meeting 20121129  
 
29-Nov-2012    AGM Presentation 29 November 2012 BXN  
 
28-Nov-2012    Extra Ordinary General Meeting To Set Future Direction  
 
20-Nov-2012    BioxyneCuts Costs To Focus On New Study  
 
12-Nov-2012    Bioxyne's Board Renewal  
 
5-Nov-2012    Initial Director's Interest Notice  
 
1-Nov-2012    Final Director's Interest Notice  
 
31-Oct-2012    Final Director's Interest Notice  
 
31-Oct-2012    Appendix 4C - quarterly  
 
30-Oct-2012    Results of Meeting  
 
29-Oct-2012    Notice of Annual General Meeting/Proxy Form  
 
26-Oct-2012    Final Director's Interest Notice  
 
25-Oct-2012    Director's Resignation  
 
24-Oct-2012    Shareholder Update  
 
8-Oct-2012    Amended Change of Director's Interest Notice  
 
5-Oct-2012    Change of Director's Interest Notice  
 
28-Sep-2012    Annual Report to shareholders  
 
24-Sep-2012    Bioxyne enters Heads of Agreement  
 
20-Sep-2012    Notice of General Meeting/Proxy Form  
 
31-Aug-2012    Preliminary Final Report  
 
31-Aug-2012    Notice of Requisition of Meeting from Wigram Trading Pty Ltd  
 
27-Aug-2012    Requisition of Meeting from Octa Philip Asset Management  
 
27-Aug-2012    Requisition of Shareholders Meeting  
 
27-Jul-2012    Appendix 4C - quarterly  
 
17-Jul-2012    Chairman's Address - slides  
 
12-Jul-2012    Investor Presentation  
 
12-Jul-2012    Update On Commercialisation Process  
 
6-Jul-2012    Chairman's Letter  
 
28-Jun-2012    Top 20 securityholders  
 
28-Jun-2012    Appendix 3B  
 
28-Jun-2012    Reinstatement to official quotation  
 
28-Jun-2012    Results of Phase 2b Study  
 
25-Jun-2012    Market Update On Suspension of Shares  
 
15-Jun-2012    Suspension from Official Quotation  
 
13-Jun-2012    Trading Halt  
 
28-May-2012    On Track To Report Clinical Trial Results In June  
 
23-May-2012    Appointment of Torreya Partners LLC  
 
8-May-2012    Initial Director's Interest Notice Jeremy L Curnock Cook  
 
26-Apr-2012    Investor Presentation  
 
24-Apr-2012    Quarterly Update and Appendix 4C  
 
18-Apr-2012    Becoming a substantial holder  
 
18-Apr-2012    Initial Director's Interest Notice  
 
16-Apr-2012    Becoming a substantial holder  
 
13-Apr-2012    Becoming a substantial holder  
 
13-Apr-2012    New Listed Drug Developer Bioxyne Postioned For Growth  
 
10-Apr-2012    Final Director's Interest Notice - Simon Taylor  
 
10-Apr-2012    Final Director's Interest Notice - Simon O'Loughlin  
 
10-Apr-2012    Initial Director's Interest Notice - William Harrison  
 
10-Apr-2012    Change of Director's Interest Notice - P Ford  
 
10-Apr-2012    Initial Director's Interest Notice - Glenn Crisp  
 
10-Apr-2012    Initial Director's Interest Notice - David Radford  
 
10-Apr-2012    Initial Director's Interest Notice - Ian Mutton  
 
4-Apr-2012    Becoming a substantial holder  
 
4-Apr-2012    New Australian Drug Developer Lists on ASX  
 
4-Apr-2012    Becoming a substantial holder  
 
3-Apr-2012    Share Trading Policy  
 
3-Apr-2012    Constitution of Company  
 
3-Apr-2012    Completion of Takeover of Hunter Immunology Limited  
 
3-Apr-2012    Pre-Quotation Disclosure  
 
3-Apr-2012    Becoming a substantial holder  
 
3-Apr-2012    Reinstatement to Official Quotation (04/04/12)  
 
3-Apr-2012    ASX Circular - Reinstatement to Official List  
 
2-Apr-2012    Change of Company Name to Bioxyne Limited  
 
28-Mar-2012    Appendix 3B  
 
28-Mar-2012    Top 20 securityholders  
 
28-Mar-2012    Range of Shares  
 
28-Mar-2012    Top 20 Option Holders  
 
23-Mar-2012    Completion of Takeover Offers and Compulsory Acquisition  
 
16-Mar-2012    Results of Meeting  
 
15-Mar-2012    Notification of Amended Timetable for Re-admission to ASX  
 
14-Mar-2012    Share Consolidation  
 
2-Mar-2012    Achievement of Minimum Subscription under Public Offer  
 
29-Feb-2012    Half Yearly Report and Accounts  
 
7-Feb-2012    Correction to Chairman's Address at General Meeting  
 
7-Feb-2012    Suspension from Official Quotation  
 
7-Feb-2012    Results of Meeting  
 
7-Feb-2012    Chairman's Address Delivered At The General Meeting  
 
7-Feb-2012    Trading Halt  
 
6-Feb-2012    Chairman's Address to Shareholders - Gen Meeting 7 Feb 2012  
 
3-Feb-2012    Extension Of Public Offer Period  
 
30-Jan-2012    First Supplementary Target's Statement By Hunter Immunology  
 
25-Jan-2012    Appendix 4C - quarterly  
 
24-Jan-2012    First Supplementary Bidder's Statement for Hunter Immunology  
 
6-Jan-2012    Replacement Prospectus  
 
6-Jan-2012    Notice of General Meeting/Proxy Form  
 
22-Dec-2011    Notice of Dispatch of Bidder's Statement  
 
21-Dec-2011    Replacement Prospectus  
 
20-Dec-2011    Appendix 3B Replacement Options  
 
15-Dec-2011    Target's Statement  
 
14-Dec-2011    Appendix 3B Public Offer  
 
13-Dec-2011    Bidder's Statement for Hunter Immunology Ltd  
 
13-Dec-2011    Prospectus to Raise a Maximum of $ 4,400,000  
 
9-Dec-2011    Issue Of Bidder's Statement in Connection with Takeover Bid  
 
30-Nov-2011    Section 708 A (6) Notice and Appendix 3B  
 
29-Nov-2011    Results of Meeting  
 
29-Nov-2011    Chairman's Address to Shareholders  
 
3-Nov-2011    Placement  
 
2-Nov-2011    Termination of Agreement with Nestec  
 
25-Oct-2011    Appendix 4C - quarterly  
 
21-Oct-2011    Notice of Annual General Meeting/Proxy Form  
 
12-Oct-2011    Reinstatement to Official Quotation  
 
11-Oct-2011    Proposed Merger Of Probiomics with Hunter Immunology  
 
11-Oct-2011    Suspension from Official Quotation  
 
7-Oct-2011    Trading Halt  
 
27-Sep-2011    Annual Report to shareholders  
 
30-Aug-2011    Preliminary Final Report  
 
29-Jul-2011    Appendix 4C - quarterly  
 
2-May-2011    PCC Response to ASX Query  
 
21-Apr-2011    Appendix 4C - quarterly  
 
28-Feb-2011    Half Yearly Report and Accounts  
 
28-Jan-2011    Appendix 4C - quarterly  
 
21-Dec-2010    Share Trading Policy  
 
16-Nov-2010    Results of Meeting  
 
16-Nov-2010    Chairman's Address to Shareholders  
 
29-Oct-2010    Registration of PCC in New Zealand for Companion Animals  
 
25-Oct-2010    Appendix 4C - quarterly  
 
27-Sep-2010    Repayment Of Convertible Notes  
 
22-Sep-2010    Annual Report to shareholders  
 
16-Sep-2010    Notice of Annual General Meeting/Proxy Form  
 
20-Aug-2010    Preliminary Final Report  
 
19-Jul-2010    Appendix 4C - quarterly  
 
11-May-2010    Press Release Chr Hansen to showcase PCC at Vitafoods Geneva  
 
11-May-2010    Chr. Hansen to introduce PCC at Vitafoods Geneva  
 
30-Apr-2010    Appendix 4C - quarterly  
 
26-Feb-2010    Half Yearly Report and Accounts  
 
28-Jan-2010    Appendix 4C - quarterly  
 
26-Nov-2009    Results of Meeting  
 
25-Nov-2009    Chairman's Address to Shareholders  
 
24-Nov-2009    CHR HANSEN PRESS RELEASE ON THE GLOBAL AGREEMENT  
 
24-Nov-2009    PROBIOMICS SIGNS AN EXCLUSIVE AGREEMENT WITH CHR. HANSEN  
 
23-Nov-2009    Trading Halt  
 
27-Oct-2009    Change of Director's Interest Notice  
 
20-Oct-2009    Appendix 4C - quarterly  
 
14-Oct-2009    Notice of Annual General Meeting/Proxy Form  
 
6-Oct-2009    Change of Director's Interest Notice  
 
30-Sep-2009    Change of Director's Interest Notice - Simon O'Loughlin  
 
30-Sep-2009    Change of Director's Interest Notice - Simon Taylor  
 
28-Sep-2009    Annual Report For The Year Ended 30 June 2009  
 
25-Aug-2009    PCC Effective In Reducing Illness in Athletes  
 
18-Aug-2009    Preliminary Final Report  
 
5-Aug-2009    Extension of Convertible Notes  
 
31-Jul-2009    Resignation of CEO  
 
21-Jul-2009    Quarterly Cashflow Report  
 
26-May-2009    Section 708A(6) Notice and Appendix 3B  
 
19-May-2009    Change of Director's Interest Notice  
 
15-May-2009    Results of Meeting  
 
12-May-2009    Private Placement  
 
12-May-2009    PCC Shown To Be Effective In Boosting Flu Vaccine In Trial  
 
30-Apr-2009    Appendix 4C - quarterly  
 
2-Apr-2009    Notice of General Meeting/Proxy Form  
 
27-Feb-2009    Half Yearly Report and Accounts  
 
13-Jan-2009    Appendix 4C - quarterly  
 
5-Dec-2008    Appendix 3B  
 
1-Dec-2008    Expiry of Unlisted Options  
 
27-Nov-2008    Change Of Director's Interest - S O'Loughlin  
 
27-Nov-2008    Change Of Director's Interest - S Taylor  
 
27-Nov-2008    Change Of Director's Interest - P Ford  
 
27-Nov-2008    Appendix 3B  
 
27-Nov-2008    Results of Meeting  
 
26-Nov-2008    Chairman's Address to Shareholders  
 
27-Oct-2008    Appendix 4C - quarterly  
 
21-Oct-2008    Notice of Annual General Meeting/Proxy Form  
 
30-Sep-2008    Annual Report 2008  
 
15-Sep-2008    Expiry of Unquoted Options and Extention of Con Notes  
 
4-Sep-2008    Response to ASX Query  
 
27-Aug-2008    Preliminary Final Report  
 
22-Aug-2008    Appendix 3B  
 
22-Aug-2008    Class Order Relief  
 
8-Aug-2008    Resignation Of Directors  
 
8-Aug-2008    Final Director's Interest Notice  
 
7-Aug-2008    Final Director's Interest Notice  
 
6-Aug-2008    Final Director's Interest Notice  
 
6-Aug-2008    Initial Director's Interest Notice  
 
5-Aug-2008    Initial Director's Interest Notice  
 
5-Aug-2008    Initial Director's Interest Notice  
 
31-Jul-2008    Market Update and Board Changes  
 
31-Jul-2008    Quarterly Cashflow Report  
 
27-Jun-2008    Change of Director's Interest Notice  
 
27-Jun-2008    Appendix 3B  
 
24-Jun-2008    Results of Meeting  
 
24-Jun-2008    Change of Registered Office Address  
 
23-Jun-2008    Chairman's Address to Shareholders  
 
13-May-2008    Notice of Annual General Meeting/Proxy Form  
 
30-Apr-2008    Commitments Test Entity - Third Quarter Report  
 
24-Apr-2008    Extension of Share Purchase Plan  
 
18-Apr-2008    Extension of Share Purchase Plan Offer  
 
16-Apr-2008    Market Update - Acquisition of Minomic International Limited  
 
7-Apr-2008    Market Update  
 
20-Mar-2008    Newsletter  
 
13-Mar-2008    Share Purchase Plan Offer Booklet and Application Form  
 
13-Mar-2008    Conditional acquisition of Minomic International Limited  
 
11-Mar-2008    Appointment of New Chief Executive Officer  
 
4-Mar-2008    Reinstatement to Official Quotation  
 
3-Mar-2008    Half Year Accounts  
 
29-Feb-2008    4 D - Half Yearly Report  
 
27-Feb-2008    Capital Raising Update  
 
31-Jan-2008    Commitments Test Entity - Second Quarter Report  
 
20-Dec-2007    Appendix 3B  
 
25-Oct-2007    Commitments Test Entity - First Quarter Report  
 
15-Oct-2007    Executes Global Finance Agreement with Nestle  
 
10-Oct-2007    Issue of Convertible Notes  
 
28-Sep-2007    Annual Report to shareholders  
 
31-Aug-2007    Preliminary Final Report  
 
30-Jul-2007    Commitments Test Entity - Fourth Quarter Report  
 
27-Jul-2007    Company Secretary Appointment  
 
1-Jun-2007    Issue of Unlisted Options  
 
3-May-2007    Lapse of Unlisted Options  
 
23-Apr-2007    Class order relief for share placement  
 
18-Apr-2007    Commitments Test Entity - Third Quarter Report  
 
13-Apr-2007    Appendix 3B  
 
23-Mar-2007    Share Placement  
 
1-Mar-2007    Lapse of unlisted employee options  
 
28-Feb-2007    Half Yearly Report & Accounts  
 
31-Jan-2007    Commitments Test Entity - Second Quarter Report  
 
1-Dec-2006    Issue of employee options  
 
29-Nov-2006    Results of AGM  
 
31-Oct-2006    Commitments Test Entity - First Quarter Report  
 
25-Oct-2006    Notice of Annual General Meeting  
 
6-Oct-2006    Lapse of Unlisted Options  
 
28-Sep-2006    2006 Annual Report  
 
22-Sep-2006    Ceasing to be a substantial holder  
 
21-Sep-2006    Issue of Options  
 
21-Sep-2006    Results of General Meeting  
 
13-Sep-2006    Preliminary Final Report  
 
15-Aug-2006    Notice of General Meeting  
 
14-Aug-2006    Class Order Relief for Placement of Shares  
 
9-Aug-2006    Appendix 3B  
 
31-Jul-2006    Commitments Test Entity - Fourth Quarter Report  
 
3-Jul-2006    Lapse of Options  
 
7-Jun-2006    Issue of employee share options  
 
27-Apr-2006    Commitments Test Entity - Third Quarter Report  
 
11-Apr-2006    Quarterly Newsletter  
 
9-Mar-2006    Half Yearly Report & Half Year Accounts  
 
7-Mar-2006    Lapse of listed options  
 
2-Mar-2006    Re-negotiates distribution contract  
 
30-Jan-2006    Commitments Test Entity - Second Quarter Report  
 
16-Jan-2006    Issue of options to Directors  
 
12-Dec-2005    Change of Director's Interest Notice  
 
12-Dec-2005    Clarification of media report on clinical trial  
 
8-Dec-2005    Appendix 3B  
 
8-Dec-2005    Lapse of employee share options  
 
24-Nov-2005    Results of AGM  
 
24-Nov-2005    Chairman's AGM Address to Shareholders  
 
24-Nov-2005    Extension of closing date of SPP  
 
23-Nov-2005    Flu vaccine clinical trial  
 
16-Nov-2005    Wins AJP Award  
 
8-Nov-2005    Receipt of Commercial Ready grant  
 
31-Oct-2005    Commitments Test Entity - First Quarter Report  
 
31-Oct-2005    Share Purchase Plan - Letter to Shareholders  
 
20-Oct-2005    Notice of Annual General Meeting  
 
30-Sep-2005    2005 Annual Report  
 
23-Sep-2005    Becoming a substantial holder  
 
23-Sep-2005    Becoming a substantial holder  
 
13-Sep-2005    Preliminary Final Report  
 
24-Aug-2005    Class order relief statement  
 
22-Aug-2005    Appendix 3B - Share Placement  
 
29-Jul-2005    Commitments Test Entity - Fourth Quarter Report  
 
29-Jul-2005    $1m Private Placement  
 
5-Jul-2005    Quarterly Newsletter to Shareholders  
 
24-May-2005    Final Director's Interest Notice  
 
24-May-2005    Appendix 3B - Issue of unlisted employee share options  
 
24-May-2005    Final Director's Interest Notice  
 
24-May-2005    Initial Director's Interest Notice  
 
20-May-2005    Board Changes & AIM Listing  
 
13-May-2005    Placement - ASIC Class Order Relief  
 
12-May-2005    Appendix 3B - Additional Working Capital  
 
2-May-2005    Amendment to previous announcement re Placement  
 
2-May-2005    Change of Trading Code to PCC  
 
2-May-2005    Fully Underwritten $1.0 million Placement & SPP  
 
2-May-2005    Commitments Test Entity - Third Quarter Report  
 
19-Apr-2005    Lapse of Employee Options  
 
11-Apr-2005    Appendix 3B - Issue of Employee Share Options  
 
8-Apr-2005    Results of General Meeting  
 
22-Mar-2005    Investor Presentation  
 
16-Mar-2005    Response to ASX Query  
 
15-Mar-2005    Product Launch boosted as FDA clamps down on competitors  
 
9-Mar-2005    Successful Completion-1st Stage Molecule Discovery Program  
 
3-Mar-2005    Initial Director's Interest Notice  
 
3-Mar-2005    Notice of General Meeting  
 
3-Mar-2005    Initial Director's Interest Notice  
 
3-Mar-2005    Initial Director's Interest Notice  
 
3-Mar-2005    Final Director's Interest Notice  
 
3-Mar-2005    Final Director's Interest Notice  
 
25-Feb-2005    Half Yearly Report & Half Year Accounts  
 
23-Feb-2005    Second Functional Food Agreement  
 
21-Feb-2005    Ceasing to be a substantial holder  
 
18-Feb-2005    Board Changes for AIM admission  
 
18-Feb-2005    Partners with Sanitarium  
 
15-Feb-2005    Trial to reduce ear infections in Aboriginal children  
 
9-Feb-2005    Becoming a substantial holder  
 
7-Feb-2005    Becoming a substantial holder  
 
31-Jan-2005    Commitments Test Entity - Second Quarter Report  
 
31-Jan-2005    VRI to List on AIM  
 
25-Jan-2005    Licensing Agreement with Largest Distributor in Asia  
 
30-Nov-2004    Form 484 - Selective reduction of capital  
 
26-Nov-2004    Appendix 3B - issue of options to a director  
 
26-Nov-2004    Final Director's Interest Notice  
 
26-Nov-2004    Results of AGM  
 
17-Nov-2004    Presentation to Investors  
 
28-Oct-2004    Commitments Test Entity - First Quarter Report  
 
25-Oct-2004    Notice of AGM & Special Meeting  
 
25-Oct-2004    Annual Report 2004  
 
30-Sep-2004    Annual Report  
 
28-Sep-2004    Rowett Research Institute project  
 
31-Aug-2004    Preliminary Final Report  
 
26-Aug-2004    Significant interest in Atopic Dermatitis Trial Results  
 
11-Aug-2004    Lapse of Options  
 
30-Jul-2004    App 3B -Part consideration for arranging placement of shares  
 
30-Jul-2004    Commitments Test Entity - Fourth Quarter Report  
 
27-Jul-2004    Appendix 3B - New issue  
 
27-Jul-2004    Disclosure Document  
 
20-Jul-2004    Amended Appendix 3B - For additional funding of operations  
 
20-Jul-2004    Placement - ASIC Class Order Relief  
 
20-Jul-2004    Appendix 3B - For additional funding of company's operations  
 
14-Jul-2004    successful Phase II Trial Results for Atopic Dermatitis  
 
12-Jul-2004    Results of Meeting  
 
6-Jul-2004    Ceasing to be a substantial holder  
 
5-Jul-2004    Death of Mr Jim Grant -Chairman  
 
21-Jun-2004    Change in substantial holding  
 
15-Jun-2004    Issue of Bonus Options to Shareholders  
 
11-Jun-2004    Chairman's Letter to Shareholders/Notice of General Meeting  
 
28-May-2004    Placement  
 
12-May-2004    Launches new proTract range of Probiotics  
 
7-May-2004    Registration of Progastrim in Singapore  
 
4-May-2004    Appointment of Medical & Scientific Advisory Board  
 
29-Apr-2004    Commitments Test Entity - Third Quarter Report  
 
30-Mar-2004    Appendix 3B - Fund companys operations  
 
29-Mar-2004    Placement & Forthcoming Rights Issue raising $2.9m  
 
15-Mar-2004    Advances Plans for Product Distribution in Asia & US  
 
27-Feb-2004    Shareholder Update from Managing Director  
 
27-Feb-2004    Half Yearly Report & Half Year Accounts  
 
5-Feb-2004    Response to ASX Appendix 4C Query  
 
28-Jan-2004    Commitments Test Entity - Second Quarter Report  
 
21-Jan-2004    Ceasing to be a substantial holder  
 


Supplier Member

Bioxyne Ltd.

Suite 506, Level 5
50 Clarence St
Sydney, NSW 2000, Australia

P: +61 2 9078 8180
E: info@bioxyne.com
ABN: 97 084 464 193

Home

Sign Up

Payment Methods

PayPal Acceptance Mark
Practitioners: Register to become our affiliate